Sodium Acetate

Phase 1Small molecule

Pfizer

Sodium Acetate is one of 38 small molecule programs targeting Insulin resistance. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Insulin ResistancePhase 1

Active, not recruiting

Competition

Competitive Landscape

169 competitors in Insulin Resistance

#DrugCompanyPhaseTrials

Edarbi

Takeda

Phase 3

1 2

Januvia

ZZydus Therapeutics Inc.

Phase 3

2 3

Jardiance

Boehringer Ingelheim

Phase 3

2 4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 5

Parlodel

VVeroScience

Phase 3

1 6

Glucophage

Boehringer Ingelheim

Phase 3

1 7

Farxiga

AstraZeneca

Phase 2

2 8

Lupron

AbbVie

Phase 2

1 9

Metformin Hcl

Boehringer Ingelheim

Phase 3

2 10

Myalept

Chiesi Farmaceutici S.p.A.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Insulin Resistance

NCT06354088

Q1 2031

Phase 3Active, not recruiting

Scar

NCT05345171

Clinical

Trials by Indication[1]

Scar1 trial

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

Active, not recruiting· Ultragenyx logo

Ultragenyx·Phase 3·NCT05345171·32 enrolled

Insulin resistance1 trial

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Recruiting·—·Phase 1·NCT06354088·32 enrolled

Regulatory

FDA Approval Timeline[4]

May 4, 1983

SODIUM ACETATE

NDA NDA018893

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sodium Acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium Acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodium Acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018893). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Pfizer

Sodium Acetate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2031

Trials by Indication[1]

Scar1 trial

Insulin resistance1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News